CancerWorld shared a post on LinkedIn:
“Science Spotlight: Why CAR-NKT Beats CAR-T in Solid Tumors
Why has CAR-T struggled in solid tumors like pancreatic cancer? Poor tumor penetration, immune suppression, and antigen escape.
CAR-NKT therapy solves all three.
By combining CAR targeting, innate immune killing, and immune microenvironment remodeling, CAR-NKT cells show superior tumor control and survival benefits — even in metastatic disease.
This may be the universal immunotherapy platform solid tumors have been waiting for.
Read the full CancerWorld article by Janet Fricker here.”
Other articles from CancerWorld on OncoDaily.